28 August 2025
: Case report 
Pancreatic Inflammation Induced by Immune Checkpoint Inhibitors in Melanoma Treatment: A Case Report
Unusual clinical course, Challenging differential diagnosis, Unusual or unexpected effect of treatment, Diagnostic / therapeutic accidents, Adverse events of drug therapy
Abdo I. El Tawil ABCDEF 1*, Beatriz A. Mendes ABCDEF 1, Leandro A.F. Machoski ABCDEF 1, Micheli F. Domingos AEF 2, Noelle S. Wassano AEF 3, Sérgio O. Ioshii AEF 4, Eduardo J.B. Ramos AEF 2DOI: 10.12659/AJCR.948580
Am J Case Rep 2025; 26:e948580
Figure 7 Comparative magnetic resonance imaging (A1–D1) before resuming nivolumab treatment (top image) and (A2–D2) after (bottom image) no longer shows significant enlargement of the pancreatic head. Coronal and axial T1- and T2-weighted post-contrast sequences (arrows) show resolution of the prior bulky pancreatic head mass and decreased peripancreatic inflammatory changes. No evidence of biliary ductal dilatation or vascular encasement is observed. Mild residual soft tissue thickening in the pancreatic head remained without diffusion restriction or significant enhancement.